Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial

被引：27
|
作者：
Spaner, David E. [1 ,2 ,3 ,4 ,5 ]
Wang, Guizhei [1 ]
McCaw, Lindsay [1 ]
Li, Yanmei [1 ]
Disperati, Patricia [6 ]
Cussen, Mary-Ann [3 ]
Shi, Yonghong [1 ]
机构：
[1] Sunnybrook Res Inst, Biol Platform, Toronto, ON, Canada
[2] Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A1, Canada
[3] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[4] Univ Toronto, Dept Med, Toronto, ON M5S 1A1, Canada
[5] Univ Toronto, Dept Immunol, Toronto, ON M5S 1A1, Canada
[6] Toronto East Gen Hosp, Toronto, ON, Canada
来源：
HAEMATOLOGICA | 2016年 / 101卷 / 05期
关键词：
chronic lymphocytic leukemia; Janus Kinases; STAT3; Ruxolitinib; Ibrutinib; Kinase inhibitors; phosphoproteome; FOLLOW-UP; RESISTANCE; THERAPY; CELLS; CLL;
D O I：
10.3324/haematol.2015.135418
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [41] A phase I/II trial of Xcellerated T CellsTM in patients with chronic lymphocytic leukemia (CLL).
    Kipps, TJ
    Castro, JE
    Wierda, W
    Keating, MJ
    Bole, J
    Meyer, J
    Roehrs, H
    Bouchard, L
    Yuan, V
    Chana, H
    Hami, L
    Bonyhadi, M
    Berenson, RJ
    Frohlich, MW
    BLOOD, 2003, 102 (11) : 109A - 109A
  • [42] Phase II trial of menogaril in patients with previously treated multiple myeloma or chronic lymphocytic leukemia
    Kucuk, O
    Kilton, L
    Wade, JL
    Blough, R
    Benson, AB
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2000, 23 (04): : 379 - 383
  • [43] A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia
    Izutsu, Koji
    Kinoshita, Tomohiro
    Takizawa, Jun
    Fukuhara, Suguru
    Yamamoto, Go
    Ohashi, Yasuo
    Suzumiya, Junji
    Tobinai, Kensei
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (03) : 408 - 415
  • [44] N9986: a phase II trial of thalidomide in patients with relapsed chronic lymphocytic leukemia
    Kay, Neil E.
    Shanafelt, Tait D.
    Call, Timothy G.
    Wu, Wenting
    Laplant, Betsy R.
    LEUKEMIA & LYMPHOMA, 2009, 50 (04) : 588 - 592
  • [45] A phase I/II trial of Xcellerated T Cells™ in patients with chronic lymphocytic leukemia.
    Castro, JE
    Wierda, WG
    Kipps, TJ
    Keating, MJ
    Bole, J
    Anderson, B
    Meyer, J
    Bonyhadi, M
    Berenson, RJ
    Frohlich, MW
    BLOOD, 2004, 104 (11) : 687A - 688A
  • [46] Phase II Trial of Subcutaneous Alemtuzumab in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia
    不详
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (03): : 202 - 203
  • [47] Cyclophosphamide followed by fludarabine for untreated chronic lymphocytic leukemia: a phase II SWOG TRIAL 9706
    M A Hussein
    H Gundacker
    D R Head
    L Elias
    K A Foon
    D H Boldt
    S M Dobin
    S R Dakhil
    G T Budd
    F R Appelbaum
    Leukemia, 2005, 19 : 1880 - 1886
  • [48] A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia
    D E Spaner
    Y Shi
    D White
    S Shaha
    L He
    A Masellis
    K Wong
    R Gorczynski
    Leukemia, 2010, 24 : 222 - 226
  • [49] A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia
    Spaner, D. E.
    Shi, Y.
    White, D.
    Shaha, S.
    He, L.
    Masellis, A.
    Wong, K.
    Gorczynski, R.
    LEUKEMIA, 2010, 24 (01) : 222 - 226
  • [50] Phase II trial of the combination of ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)
    Falchi, Lorenzo
    Keating, Michael J.
    Badoux, Xavier C.
    Wierda, William G.
    O'Brien, Susan Mary
    Smith, Susan C.
    Wen, Sijin
    Kantarjian, Hagop
    Ferrajoli, Alessandra
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345